FDA approves Dupixent for bullous pemphigoid
by Lori Solomon edited by Stephanie Baum, reviewed by Andrew Zinin The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 study. Patients with moderate-to-severe bullous pemphigoid were randomly assigned to receive Dupixent 300 mg […]
FDA approves Dupixent for bullous pemphigoid Read More »
